Hypertrophy Cardiomyopathy: A Historic Disease with New Therapies (2026 AC Live)

Includes a Live Web Event on 10/07/2026 at 7:00 PM (EDT)

Only available as part of a package

Learning Objectives:

Recognize the clinical, electrocardiographic, and echocardiographic features that should prompt evaluation for hypertrophic cardiomyopathy, and distinguish HCM from other causes of left ventricular hypertrophy including hypertensive heart disease, athlete's heart, aortic stenosis, and cardiac amyloidosis.
Apply guideline-directed initial management for symptomatic obstructive HCM — including appropriate use of negative inotropes, medications and physiologic states to avoid, and the emerging role of cardiac myosin inhibitors — and identify which patients warrant referral to a comprehensive HCM center.
Describe the components of sudden cardiac death risk stratification in HCM and outline the recommended approach to genetic testing and cascade screening of first-degree relatives. Understand current exercise recommendations regarding hypertrophic cardiomyopathy.

Robby Wu, DO (he/him/his)

Advanced Heart Failure and Transplant Cardiologist

University of South Florida and Tampa General Hospital

Robby Wu, DO, is an assistant professor of medicine at the University of South Florida Morsani College of Medicine and an advanced heart failure and transplant cardiologist at Tampa General Hospital. He serves as medical director of Tampa General's Hypertrophic Cardiomyopathy Program and as associate program director of the USF Advanced Heart Failure and Transplant Cardiology fellowship.

Dr. Wu completed his undergraduate degrees in science and psychology at Pennsylvania State University and earned his medical degree at the Philadelphia College of Osteopathic Medicine in Philadelphia. He trained in internal medicine at Danbury Hospital, Yale School of Medicine, followed by a cardiovascular disease fellowship at Northside Hospital and the Tampa Bay Heart Institute and an advanced heart failure and transplant cardiology fellowship at Tampa General Hospital, USF Morsani College of Medicine. He is board certified in internal medicine, cardiovascular disease, and advanced heart failure and transplant cardiology, and is a diplomate of the National Board of Echocardiography.

His clinical and research interests span advanced heart failure, heart transplantation, mechanical circulatory support, and inherited cardiomyopathies. He serves as principal investigator on several multicenter trials, including SONATA-HCM, COMET-HF, and DRAIN-HF. His work has appeared in JACC: Heart Failure and the Journal of Heart and Lung Transplantation, and he has been invited to speak on hypertrophic cardiomyopathy, cardiogenic shock, and mechanical circulatory support at several national conferences.

Dr. Wu serves on the American College of Cardiology's Advanced Heart Failure and Transplant Cardiology Committee, chairs the USF Heart Failure Education Committee, and reviews for the Journal of Cardiac Failure. In 2025 he was named an American Heart Association Leader of Impact for Tampa Bay.

The faculty member, for this activity, has disclosed the following financial relationships: